Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Halozyme Therapeutics Q2 Adj. EPS $1.54 Beats $1.23 Estimate, Sales $325.719M Beat $281.588M Estimate

Author: Benzinga Newsdesk | August 05, 2025 04:03pm
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.23 by 25.2 percent. This is a 69.23 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $325.719 million which beat the analyst consensus estimate of $281.588 million by 15.67 percent. This is a 40.79 percent increase over sales of $231.353 million the same period last year.

Posted In: HALO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist